Rapport Therapeutics (RAPP) Net Cash Flow (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Net Cash Flow data on file, last reported at $25.4 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 3080.35% year-over-year to $25.4 million in Q1 2026; TTM through Mar 2026 was $20.5 million, a 222.74% increase from a year earlier, with the FY2025 full-year figure at -$4.2 million, up 68.82% from the prior year.
• Net Cash Flow for Q1 2026 stood at $25.4 million, up from -$198.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for RAPP reached as high as $196.3 million in Q3 2025 and fell as low as -$198.7 million in Q4 2025.
• Historically, Net Cash Flow has averaged -$124272.7 across 4 years, with a median of $4.1 million in 2024.
• Across the five-year window, Net Cash Flow slumped 1236.09% in 2025 and jumped 3080.35% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$89.2 million in 2023, then surged by 119.62% to $17.5 million in 2024, then slumped by 1236.09% to -$198.7 million in 2025, then jumped by 112.79% to $25.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $25.4 million in Q1 2026, -$198.7 million in Q4 2025, and $196.3 million in Q3 2025.